This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the pursuit of attractive equity returns, privateequity firms have developed numerous innovative strategies beyond typical leveraged buyouts and take-private transactions. As it happens, this is an industry that has experienced a significant amount of privateequity-backed roll-up activity.
When you hear the words “healthcare privateequity,” two thoughts probably come to mind: Wait a minute, isn’t healthcare a risky/growth-oriented sector? In most of the world, healthcare is either government-run or a mixed public/private sector. Are there many private healthcare companies for PE firms to acquire?
This article focuses on how medical practices are valued by privateequity-backed groups, and to an extent, health systems and other strategic acquirers. Physician practices are almost always valued on a multiple of EBITDA basis in transactions with privateequity groups or similar buyers.
Update on PrivateEquity and Insurance Brokerages In our ,, previous article , we reported that the COVID-19 pandemic had not diminished the pace of mergers and acquisitions transactions we are seeing in the insurance agency and brokerage sector. The number of transactions we are working on has not abated.
Inflation, supply chain disruptions and the rising cost of debt stopped consumer companies in their tracks last year. But some subsectors, such as beauty, fragrance, residential services and medical spas, remained active as risk-off investors shifted deal activity toward categories they view as less discretionary, according to Leonhardt.
Number of investments a year: Approx 10 Examples of previous investments: White Label Loyalty, Previsico, The Bunch, Beaconsoft and LightPoint Medical. Number of investments a year: 15 Examples of previous investments: Chargemaster, Ebury, Pod, PayasUgym, PowerX and Lightpoint Medical. Contact: john@advantagebusinessangels.co.uk
The fund will not invest in hardware, medical devices or consumer social networks. Can provide a mixture of equity and mezzanine debt to businesses mostly at the Series A stage. Entrée Capital Entrée Capital invests predominantly in software, with a current focus in enterprise, SaaS, marketplaces, big data and fintech.
The higher interest rates escalated borrowing expenses, making mega-deals (deals valued at $5 billion or more) significantly more expensive, due to their heavy reliance on debt financing, and impacted valuation multiples with higher discount rates. The aggressive rate hikes contributed to the decline in M&A activity in 2023.
However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined privateequity sponsor buyers. trillion. [2]
Vice Chancellor Lasters opinion captioned In re Dura Medic Holdings, Inc. The case involved claims brought by a co-founder of Dura Medic, Inc. Dura Medic or Company) against affiliates of Comvest, a privateequity backer that acquired Dura Medic in 2018 through subsidiary affiliates.
Vice Chancellor Lasters opinion in In re Dura Medic Holdings, Inc. The case involved claims brought by a co-founder of Dura Medic, Inc. Dura Medic or Company) against affiliates of Comvest, a privateequity backer that acquired Dura Medic in 2018 through subsidiary affiliates.
Consumer retail privateequity is so diverse that it almost seems like a paradox. Depending on the firm, a consumer retail privateequity deal might consist of: A leveraged buyout of a struggling offline retailer. On the Job Recruiting Should You Go Shopping for Consumer Retail PrivateEquity Jobs?
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content